Page last updated: 2024-12-07
violapterin
Description
Violapterin is a natural product isolated from the violet species *Viola tricolor*. It exhibits a range of biological activities, including antimicrobial, anti-inflammatory, and antioxidant properties. It is known to inhibit the growth of various bacteria and fungi, and its potential as a therapeutic agent is being explored. Violapterin's complex structure and unique biological activities have made it a target for synthetic studies. Researchers are investigating its synthesis to develop new and potentially more potent analogs with improved pharmacological profiles. The study of violapterin aims to understand its mechanism of action and explore its potential as a drug lead for various diseases. Its anti-inflammatory effects are particularly promising, and research focuses on its ability to modulate inflammatory pathways and suppress inflammatory responses in various disease models.'
2,4,7-trihydroxypteridine : A member of the class of pteridines that is pteridine in which the hydrogens at positions 2, 4, and 7 have been replaced by hydroxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 75734 |
| CHEBI ID | 85515 |
| SCHEMBL ID | 5443522 |
| MeSH ID | M0121370 |
Synonyms (26)
| Synonym |
|---|
| nsc 405591 |
| 3h368n1b88 , |
| unii-3h368n1b88 |
| 2,4,7-pteridinetriol |
| 2,4,7-trihydroxypteridine |
| isoxantholumazine |
| lumazine, 7-hydroxy- |
| nsc405591 |
| 2,7(1h,3h,8h)-pteridinetrione |
| nsc-405591 |
| 2577-38-0 |
| 2,7-pteridinetriol |
| 2,7-trihydroxypteridine |
| violapterin |
| 7-hydroxylumazine |
| 1,8-dihydropteridine-2,4,7-trione |
| 2,4,7(1h,3h,8h)-pteridinetrione |
| SCHEMBL5443522 |
| BCVUYVOMXUKYFC-UHFFFAOYSA-N |
| pteridine-2,4,7-triol |
| CHEBI:85515 |
| DTXSID30180440 |
| Q27158614 |
| pteridine-2,4,7(1h,3h,8h)-trione |
| 1,2,3,4,7,8-hexahydropteridine-2,4,7-trione |
| STARBLD0004690 |
Drug Classes (2)
| Class | Description |
|---|
| pteridines | |
| heteroaryl hydroxy compound | Any organic aromatic compound having one or more hydroxy groups attached to a heteroarene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.46 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.25 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |